Skip to main content
. 2015 Dec 14;10(12):e0144500. doi: 10.1371/journal.pone.0144500

Fig 1. PAR-2 expression on monocytes and severe asthma.

Fig 1

A. Gating strategy to study PAR-2 expression on peripheral blood monocytes. B-C. Percentage of CD14++CD16+ (B) and CD14++CD16- (C) monocytes in the peripheral blood of severe asthmatics compared to mild/moderate asthmatics. D-E. PAR-2 expression on CD14++CD16+ (D) and CD14++CD16- (E) monocytes in patients with mild/moderate and severe asthma. F-G. Percentage of CD14++CD16+PAR-2+ (F) and CD14++CD16-PAR-2+ (G) monocytes in peripheral blood of patients with mild/moderate and severe asthma. H-I. PAR-2 MFI on CD14++CD16+ (H) and CD14++CD16- (I) monocytes from patients with mild/moderate and severe asthma. Data is presented as boxplots (n = 24 for mild/moderate and n = 12 for severe asthma). Statistical significance was assessed by Mann-Whitney rank sum test, with P<0.05 considered significant.